BioSpace News Archive

Aesculap Implant Systems, LLC today announced that it has been five years since the organization received FDA approval to market the activL® Artificial Disc in the United States.

Neauvia North America announces the release of NPURE, an FDA Class I medical device in the U.S. Market to address the need for additional disinfection methods in a COVID-19 environment. [18-June-2020] RALEIGH, N.C. , June 18, 2020 /PRNewswire/ -- Neauvia North America has announced that NPURE is a Food and Drug Administration (FDA) Class I device that offers the wel

Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that, further to its press releases of January 17, 2019 and December 4, 2019, its proposal entitled “DispersinB® the missing link in wound care – Clinical evaluation of DispersinB®

The Lausanne University Hospital and IntraOp Medical Corporation have announced a research and development collaboration to accelerate the development of FLASH radiotherapy toward first human trials.

Researchers at Montefiore Health System and Albert Einstein College of Medicine, in collaboration with four major New York City academic health centers, published the largest review to date of birth outcomes among women with SARS-CoV-2, the novel coronavirus.

A June 4, 2020 study published in Plos Pathogens reveals that women taking antibiotics for BV may be able to improve treatment outcomes if vaginal probiotics with Lactobacillus are taken in conjunction.

OpenCell Technologies, an R&D-stage biomedical venture, has announced the hiring of Kevin Gutshall as CEO

Livongo Health, Inc. (Nasdaq: LVGO), the leading Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced the findings of two studies that demonstrate how remote monitoring technologies can utilize continuous and unique data insights via its AI+AI® engine to better inform care decisions and outcomes. The research findings were presented at the American Diabetes Associati

Epizyme, Inc. (Nasdaq:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for TAZVERIK™

Scientists have further decoded how mammalian brains perceive odors and distinguish one smell from thousands of others.